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Inactivated Foot-and-Mouth Disease (FMD) vaccine has proven to be effective in the
control of the disease. However, its production has some disadvantages, including the
costly biosafety facilities required for the production of huge amounts of growing live virus,
the need of an exhaustive purification process to eliminate non-structural proteins of the
virus in the final formulations in order to differentiate infected from vaccinated animals and
variable local regulatory restrictions to produce and commercialize the vaccine. Thus, a
novel vaccine against FMD that overcome these restrictions is desirable. Although many
developments have been made in this regard, most of them failed in terms of efficacy
or when considering their transferability to the industry. We have previously reported
the use of transient gene expression in mammalian cells to produce FMD virus-like
particles (VLPs) as a novel vaccine for FMD and demonstrated the immunogenicity
of the recombinant structures in animal models. Here, we report the optimization of
the production system by assaying different DNA:polyethylenimine concentrations, cell
densities, and direct and indirect protocols of transfection. Also, we evaluated the
reproducibility and scalability of the technology to produce high yields of recombinant
VLPs in a cost-effective and scalable system compatible with industrial tech-transfer of
an effective and safe vaccine.
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INTRODUCTION
Foot-and-Mouth Disease (FMD) is a highly contagious and threatened disease of cloven-hoofed
animals, endemic in many parts of the developing world (1). It is one of the most important animal
health concerns from an economic point of view and continues to pose a serious threat to farmers,
livestock industries and governments. The presence of the disease in developing countries results
in severe restrictions to the international trade and an outbreak in FMD-free countries can cause
billionaire losses. Vaccination programs in endemic countries or those FMD free with vaccination
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consider annual or semi-annual vaccination with conventional,
inactivated vaccines. The policy of applying vaccination to
respond to incursions in FMD free countries, known as
“vaccination to live,” gained acceptance as a result of public
questioning after the slaughter of millions of animals due to
large outbreaks in Europe in 2001 (2, 3). Vaccination is useful
in many possible scenarios: for prevention or control of an
outbreak in FMD-free areas and for the control of the disease in
endemic regions.
The currently marketed inactivated virus vaccine consists
of chemically inactivated virus formulated, in most of the
cases, in oil-based adjuvant (4). For this type of vaccines, baby
hamster kidney-21 (BHK-21) cells are grown in large scale
bioreactors and then are infected with a specific Foot and Mouth
Disease Virus (FMDV) strain. The virus obtained after this
process is inactivated with binary ethyleneimine (BEI) and after
purification can be used for vaccine formulation. Although the
inactivated vaccines are effective to control the disease, they
have many disadvantages that have prompted the development
of novel vaccines (5, 6). These disadvantages include the need
of costly biosafety facilities that require constant investment
in manufacturing plant up-grades and qualified personnel as
well as strict controls to eliminate the possibility of viral
incomplete inactivation. In addition, rigorous purification steps
during production are needed to avoid the presence of FMD
viral non-structural proteins in the final formulation and thus
later be able to differentiate between infected and vaccinated
animals. Another important issue is that related to the policies
of regulatory sanitary agencies across many FMD-free regions
and countries, which restrict the production of growing live
virus in their mainland. Finally, other key obstacles include the
high variability of the virus and the lack of cross protection
between serotypes or in some cases between members of the
same serotype.
FMDV is a non-enveloped positive-sense single-stranded
RNA virus, member of the Picornaviridae family and genus
Aphthovirus (7). FMDV is classified into seven serotypes: A,
O, C, SAT1, SAT2, SAT3, and ASIA1, and into many subtypes
within each serotype (8). FMDV structural proteins are encoded
by the polyprotein P12A and assembled to form the icosahedral
capsid after protease 3C cleavage of P12A into mature VP0,
VP3 and VP1. Finally, after RNA encapsidation, VP0 is cleaved
into VP2 and VP4 and the infectious viral particle is assembled.
One copy of each structural protein forms a protomer (5S),
five protomers (12S) form a pentamer and twelve pentamers
form the empty capsid (75S). Most of the novel developments
in FMD vaccines are based on recombinant empty capsids
(also referred as virus-like particles, VLPs). These VLPs are
promising alternative antigens for vaccine development because
they mimic the viral structure and have the complete repertoire
of epitopes in a particulate and repetitive form but lacking the
infectious RNA (9). Many expression systems and recombinant
strategies, including baculovirus expression in cells and larvae,
bacterial expression using SUMO technology, DNA vaccines and
viral vector vaccines -especially using adenovirus-, have been
developed to produce a novel FMD vaccine based on VLPs
(10). Moreover, several researchers have already demonstrated
the immunogenicity of this recombinant structures produced
in various expression systems and with different strategies (11–
18). Among these strategies, the most advanced technologies
include the use of a baculovirus expression system in insect
cells and adenovirus vector vaccines. Using the baculovirus
expression system, a novel mutation in the VP2 sequence of
FMDV serotype A has been reported to produce thermostable
VLPs which is especially helpful in some developing countries
where maintaining the cold chain for vaccine distribution can
be complicated (14). Regarding viral vector vaccines using
adenovirus technology for serotype A, there is already a license
in the USA for emergency use in case of an outbreak (5,
18, 19). We have previously demonstrated that VLPs based
on A2001 Argentina strain, produced using transient gene
expression (TGE) in suspension-growing cells, were able to elicit
an immune response in a mouse model with a 100% protection
after viral challenge, a response comparable to the one obtained
using a similar amount of inactivated virus (20). We have also
recently demonstrated the immunogenicity of FMDV VLPs in
cattle (21).
The traditional way of producing recombinant proteins
in mammalian cells is the development of stable cell lines
(22, 23). However, toxic proteins like protease 3C do not
allow the development of stable cell lines. In this context,
TGE is a simple and fast technology for the production
of recombinant proteins, which was developed to produce
mg of proteins for the first steps in clinical trials and thus
represents the strategy of choice for mammalian cell expression
of toxic proteins (24). In the case of FMD novel vaccines,
TGE has some advantages because the process itself is quite
similar to the current production of the inactivated virus
but the preparation of viral seeds and infection of cells are
replaced by plasmid production and transfection, respectively.
The possibility of fast cloning the P12A sequence of different
serotypes into the expression plasmid makes TGE a promising
technology for the development of a novel vaccine against
FMD, especially in emergency scenarios where fast responses
are required.
Although many of the efforts made to develop a novel VLP-
based vaccine for FMD have shown promising results, the
challenge is still to have a novel vaccine that is as effective as
the currently marketed inactivated one but produced with simple
and scalable technology to encourage the tech-transference steps
required to move from bench to market. These key aspects
of novel strategies are scarcely reported. Considering that it
is now generally accepted that VLPs are the best recombinant
antigens to produce a novel vaccine against FMD, it is desirable to
show the simplicity and scalability of the different recombinant
technologies in order to make them attractive to the industry.
Thus, the aim of this work was to make an effort in this
regard by moving forward to increasing the yield of VLPs from
TGE by using codon-optimized plasmids and assaying different
DNA:polyethylenimine (PEI) concentrations and cell densities.
We also assayed direct and indirect protocols, evaluated the
addition of an antiapoptotic gene in the transfection mixture,
and focused on the reproducibility and scalability of the already
reported technology. Finally, we performed vaccine formulation
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The human embryonic kidney 293 cell line stably expressing a
truncated Epstein–Barr virus Nuclear Antigen-1 (293-6E cells)
was grown in suspension in serum-free F17 medium (Gibco),
as previously described (20). Cells were grown in a humidified
incubator at 37◦C with 5% CO2, with agitation at 120 rpm.
Plasmids
FMDV DNA sequences were cloned under the CVM promoter
in the pTT5 vector (25). The pTT5-P12A3C plasmid encoding
wild type sequences from FMDV A2001 Argentina strain
was previously constructed (20). The P12A sequence from
FMDV A2001 was codon-optimized for mammalian expression
by GenScript (Supplementary Data) and the synthetic gene
encoding P12A was subcloned in the pTT5 vector with protease
3C in tandem by digesting the pTT5-P12A3C wild type with
the restriction enzymes NheI and BstBI. A Kozak sequence
was included immediately upstream the start codon. pTT22-
hAktDD encoding a constitutively active Akt mutant was co-
transfected as described previously (23, 26). Escherichia coli
(DH5α) grown in Circle Grown medium (MP Biomedicals,
Solon, OH, USA), supplemented with 50µg/mL ampicillin
was used for plasmid production. The plasmid was purified
using MAXI prep columns (Qiagen, Mississauga, ON, Canada)
according to the manufacturer’s instructions. The A260/A280
ratios were measured and only plasmid preparations with ratios
between 1.75 and 2.00 were used.
Production of Recombinant VLPs
293-6E cells were transfected using polyethylenimine (LPEI-
MAX) (Polysciences, Warrington, PA, USA), as previously
reported (20). Briefly, cells were seeded 2 days before transfection
at 0.45–0.5 × 106 cells/mL. The day of transfection, viability
and cell densities were determined. Only cells with viability
>95% and densities between 1.5 and 2 × 106 cells/mL were
transfected. For the indirect protocol: the plasmid and PEI
were diluted in complete medium and PEI was added to the
DNA dilution and mixed. After incubation at room temperature
for 3min, the DNA:PEI mixture was added to the culture.
For the direct protocol: the plasmid and PEI were diluted in
complete medium and added to the cell cultures (27). Shake
flasks of different volumes (125, 250, 500mL, and 1 L) and a 10 L
Bioreactor were used for the transfection. Cells were harvested,
centrifuged and resuspended in lysis buffer (50mM HEPES pH
7.4, 150mM NaCl, 1% Thesit, 0.5% NaDeoxycholate). The use
of PEI for transfection may be covered by existing intellectual
property rights, including the US Patent 6,013,240, the European
Patent 0,770,140, and foreign equivalents, for which further
information may be obtained by contacting licensing@polyplus-
transfection.com.
Cell Counts
Cell density and cell viability were measured using an automated
cell counter, Cedex Analyzer, based on the trypan blue exclusion
method (Roche, Laval, Qc).
Recombinant Protein Analyses
For Western Blotting analysis, lysates were separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
Then, proteins were transferred onto a polyvinylidene difluoride
membrane, blocked and then incubated with anti-FMDV guinea
pig serum (1/500) produced in house using wild type inactivated
FMDVA2001 Argentina strain. After several washes, membranes
were incubated with horseradish peroxidase-conjugated anti-
guinea pig goat serum (1/1,000) (KPL). The reaction was
visualized with an enhanced chemiluminescence method in
a GBox (Syngene). The VLPs were quantified by enzyme-
linked immunosorbent assay (ELISA). For coating of microtiter
plates (Maxisorp), a polyclonal anti-FMDV serum made in
rabbit (1/3,000) was diluted in carbonate-bicarbonate buffer, pH
9.6, and incubated at 4◦C overnight. The washing steps were
done with phosphate-buffered saline (PBS) 0.1% Tween-20 and
blocking for 30min at 37◦C with 5% normal equine serum
in PBS 0.1% Tween-20. Samples were incubated at 37◦C for
1 h. For the generation of standard curves, known amounts of
inactivated FMDV were serially diluted and added to the wells.
Plates were then incubated for 1 h with a polyclonal anti-FMDV
serum made in guinea pig (1/3,000), followed by horseradish
peroxidase-conjugated anti-guinea pig goat serum (KPL). Then,
tetramethylbenzidine was added and, 5min later, the reaction
was stopped with sulfuric acid 12%. Absorbance at 450 nm
(A450) was recorded in a microplate reader (Thermo Scientifics
MultiskanFC). For gradient assembly, 1mL of 45, 35, 25, and
15% sucrose solutions (W/V) was added to ultracentrifuge
tubes Ultra-Clear tubes 1/2 × 2 in (13 × 51mm). The most
concentrated solution was located at the bottom of the tube and
the most diluted at the top. Samples were added on top of the
gradient. The tubes were centrifuged in a BeckmanOptima-LPX-
100 Ultracentrifuge using a SW 55 Ti rotor for 2 h at 45,000 rpm
at 4◦C, acceleration: 9, deceleration: 9. Once the centrifugation
was completed, 0.5mL aliquots were collected. Aliquots were
tested for ELISA-specific FMDV protein. Both the gradient
assembly and the sample collection were performed manually.
Vaccine Formulation
Cells were harvested, centrifuged at 4,000 g and the supernatant
was discarded. Pellets were resuspended in Tris-salt buffer and
subjected to three freeze-thaw cycles at −80/25◦C. Finally, the
lysate was clarified by centrifugation and VLPs were quantified
by ELISA as described above.
For the vaccine formulation, a water-in-oil (W/O) single
emulsion was prepared by adding the formulated aqueous phase
containing the VLPs to the oily phase containing mineral oil
and emulsifier agents. The mixture was then emulsified using
an UltraTurrax homogenizer for 8 s at full speed. The particle
size distribution of the final emulsion was analyzed by laser
diffraction using the Mastersize 2000 (Malvern). To obtain the
aqueous phase for analysis, the emulsion was disrupted by adding
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1 volume of chloroform in a 15mL tube. The blend was mixed
gently up and down for 1min and centrifuged for 10min at
4,000 rpm. The aqueous phase was collected and the procedure
of adding chloroform was repeated. The VLPs in the recovered
aqueous phase were evaluated by sucrose gradient and quantified
by ELISA as described above.
RESULTS
Optimization of FMDV VLPs
First, we compared the VLP yield obtained using wild type
viral sequences and codon-optimized synthetic sequences for
mammalian cells encoding for FMDV proteins. The expression
levels achieved with the optimized sequence were slightly higher
than those achieved with the wild type sequence, although the
codon adaptation index changed from 0.74 to 0.95 (data not
shown). So, after that, all the experiments shown were performed
with the codon-optimized sequence.
To further optimize the VLP yield achieved by TGE, we
evaluated different DNA:PEI concentrations in both direct
and indirect protocols, using the pTT5-P12A3C plasmid. Also,
considering the toxic effects of protease 3C on cells, we tested
the effect of the addition of an antiapoptotic gene (AKT)
in the transfection mixture (Figure 1A) (23, 28). Among all
FIGURE 1 | (A) Evaluation of different DNA:PEI concentrations (µg/ml) in both direct and indirect protocols and effect of the addition of an antiapoptotic gene AKT in
the transfection mixture. (B) Evaluation of different cell densities using the pTT5-P12A3C plasmid plus AKT, using different DNA:PEI concentrations. Cell cultures with
3 and 4 × 106 cells/mL were produced using cultures with a cell density of 2 × 106 cells/mL and centrifugation steps before transfection. The increase in VLP yield
was measured by Western Blotting analysis of the VP0 band intensity, comparing each transfection with the transfection condition previously published in
Mignaqui et al. (20).
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FIGURE 2 | (A) Experimental design of the reproducibility assay. After vials were thawed, cells were grown for 3 weeks, mimicking the passages needed to achieve a
volume of around 5,000 L. After 7 passages, cells were transfected and, at 48 hpt, cells were harvested for protein analysis. WCB, Working cell bank. (B) Average of
viable cells × 106/mL and viability (%) of cell cultures on the day of transfection and on the harvest day (48 hpt).
the conditions evaluated, the highest increase in yield was
around 2-fold higher than that obtained by the use of the
pTT5-P12A3C plasmid in previously reported conditions and
was achieved when the antiapoptotic gene was added in the
transfection mixture. Overall, indirect transfection protocols
yielded higher recombinant VLPs levels. However, using a
direct protocol with a DNA:PEI mixture of 1.5:3.75µg/ml
we obtained 50% of increase in the VLP yield per mL
of cell culture. The advantage of the direct protocol is
that the DNA:PEI mixture step is avoided because the
procedure implies the direct addition of DNA and PEI to the
cell culture.
Then, we evaluated different cell densities and different
DNA:PEI ratios and used a combination of pTT5-P12A3C plus
15% of a plasmid encoding AKT for the transfection, which
allowed us to further increase the recombinant VLP yield
(Figure 1B). Indeed, the highest yield was achieved when the
highest number of cells was used.
Reproducibility and Scalability of FMDV
VLPs
To study the reproducibility and scalability of our technology,
we prepared a working cell bank with vials with 10 million cells
per mL. Then, independent assays were performed by starting
cell cultures using four cryovials of the working cell bank. After
thawing the cryovials, cells were grown for three weeks at low
scale (final volume 50mL), mimicking the cell passages needed
to achieve a 5,000 L culture (Figure 2A). Only cells from one
vial were also grown to different volumes: 20, 50, 200, 500mL,
and 10 L. Moreover, we performed the transfection by using
independent DNA:PEI mixtures. Cell counts and viability were
recorded during cell growth, on the day of transfection, and on
the harvest day (Figure 2B). VLP expression was analyzed by
ELISA, Western Blotting and sucrose gradient (Figures 3A,B).
The growth curves and viability of the different cultures during
cell passages during the 3-week period were similar to each
other (data not shown). On the transfection day, cell density
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FIGURE 3 | (A) Western Blotting of cell lysates (l) and supernatants (s) after 48 h of independent transfections of different culture volumes (10 L, 500, 200, 20, and
50mL) with FMDV-encoding plasmids. Primary antibody: anti-FMDV polyclonal serum made in guinea pig (1/500) and secondary antibody: anti-guinea pig peroxidase
(1/10,000). (B) Cell lysates of cultures of independent transfections of 50mL at 48 hpt analyzed by sucrose gradient to evaluate VLPs formation. Black arrows indicate
12s or 75s peak, corresponding to structural proteins assembled in pentamers or in complete empty capsids, respectively.
was between 1.5 and 2 × 106 cells/mL and viability >95%,
respectively, in all cell cultures. When cells were harvested at 48 h
post-transfection (hpt), cell density and viability were similar in
all the flasks, with a viability of 42% in average, which is very
low and confirms the toxic effects of FMDV proteins, especially
protease 3C, on cells. When 20 or 50mL were transfected, the
distribution of VLPs between the supernatant and the lysate
was around 20 and 80%, respectively. However, when the
transfection volume increased, the specific protein detected in
the supernatant also increased, being around 60% in the 10 L
bioreactor. Probably, the shear stress in the 10 L bioreactor was
stronger than in the 50mL transfection, thus, if the bioreactor is
used, the harvest time should be further optimized. Interestingly,
VLP formation was reproducible in the four 50mL transfections,
as determined by sucrose gradient analysis, with more than 92±
8% of the structural proteins assembled in VLPs. Overall, we were
able to demonstrate high reproducibility and scalability of the
technology for the production of FMDV VLPs. The maximum
recombinant protein yield in cell lysates was measured by ELISA
being 7± 0.6mg per liter of cell culture.
Vaccine Formulation and Antigen Stability
To evaluate the stability of the antigen after the process of
vaccine formulation, we prepared a W/O emulsion containing
25 µg of VLPs per dose of vaccine. Then, the emulsion was
disrupted by the addition of chloroform, and the VLPs present
Frontiers in Veterinary Science | www.frontiersin.org 6 September 2020 | Volume 7 | Article 601
Mignaqui et al. FMDV VLPs in Mammalian Cells
FIGURE 4 | Sucrose gradients showing antigen stability of VLPs within a water-in-oil emulsion vaccine after disruption.
in the recovered aqueous phase were analyzed by sucrose
gradient and quantified by ELISA (Figure 4). The percentages
of complete empty capsids (75s) and pentamers (12s) were
calculated. Immediately after the vaccine formulation and the
subsequent disruption of the emulsion, 84% of the antigen
was present as complete empty capsids. Thus, we were able to
demonstrate that a high proportion of the VLP antigen is stable
after the emulsification procedure of vaccine formulation.
DISCUSSION
FMD, one of the most devastating diseases of livestock, can cause
significant economic losses worldwide, and represents the most
important limitation to international trade in live animals and
animal products. Although the traditional inactivated vaccine
has been proved effective, the development of a novel FMD
vaccine that is effective, safer and less expensive than traditional
vaccines could be of great value. The feasibility of a tech
transfer to occur in the veterinary vaccine technology field
after a novel vaccine has proven to be effective relies mostly
on the simplicity, scalability and cost-effective properties of
the proposed technology. Regarding FMD, many efforts have
been made to develop a novel vaccine that overcomes the need
of producing huge amounts of growing live virus in costly
biosecurity facilities (5, 6, 10). Tomove from bench tomarket, the
efforts made to develop a novel vaccine against FMD must focus
in production aspects related to regulatory concerns, scalability
aspects, and cost-effective technology. Here, we focused in the
yield of recombinant VLPs, the production procedure, and
the reproducibility and scalability of the technology. Although
technical details are necessary for an efficient transfer to large-
scale production, there are few reports that address them. Most
of the efforts have been made to demonstrate that VLPs are the
antigens of choice for a novel vaccine for FMD and currently
there is relevant evidence that demonstrates that their particulate
structure and the complete presence of viral epitopes make
them as immunogenic (or almost as immunogenic) as the
virus (11–18).
The technology here described could be a great response for
emergency vaccines. When an outbreak occurs, the genomic
analysis of the viral strain responsible for the outbreak would be
enough to start the production of VLPs after a synthetic gene is
ordered and cloned into the expression plasmid. After plasmid
production by E. coli transformation and purification by anion
exchange chromatography, cells are transfected, and VLPs are
harvested at 48 hpt, The technology allows the optimization of
different aspects like the DNA:PEI ratio or the cell density, and
the use of direct protocols not only to increase the yield but
also to have a more convenient process. Here, we demonstrated
that direct transfection protocols can be used, which is a great
advantage in case large volumes are transfected because they
avoid the step of forming DNA:PEI polyplexes outside the
bioreactor (27). Generally, these polyplexes are made in 5–10% of
the final volume transfected. So, if the final volume of transfection
is 10 L, the polyplex mixture will range between 0.5 and 1 L.
Performing the mixture in a flask up to that volume can be
possible but doing so with higher volumes would require an extra
reactor. In the present study, increasing cell density was effective
in increasing the VLP yield. However, the need to concentrate the
cell cultures by a centrifugation step is not suitable for large-scale
processes. Another key element that should be further studied is
the reproducibility of the amount of VLPs produced. In the four
independent experiments here performed, we demonstrated that
the amount of VLPs obtained was high. There is little information
about this key point in other reported technologies.
All novel reported recombinant technologies avoid the need
of growing live FMDV with the reduced need of biosecurity
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level in the production facilities. However, the issues related
to the high variability of the virus have not yet been solved.
Interestingly, in the case of TGE, the cloning of P12A sequences
of different FMDV into the pTT5 vector can be easily achieved
to produce different FMDV serotypes. TGE also allows solving
problems related to the adaptation of the virus to the cell
culture but further research should be done to demonstrate the
recombinant expression of more serotypes. Each technology for
VLP production has advantages and disadvantages and thus each
could be useful in different situations considering the complex
scenario of FMD. Here, we demonstrated the robustness of
TGE and the many possibilities that can be used to improve
the technology to optimize the yield and make it suitable for
technology transfer. To go further, we were able to demonstrate
that a high proportion of VLPs produced by this technology
was stable after being subjected to the emulsification process of
water-in-oil vaccines, which is the type of formulations usually
used for traditional inactivated FMD vaccines. Although some
decrease in the integrity of VLPs was observed after rupture of
the emulsion, it must be considered that this procedure can be
quite aggressive, and maybe the decrease in VLPs can be an
artifact of the techniques used for the analysis. Further studies
in target species must be performed in order to continue with
the characterization of the vaccine. Overall, these results suggest
the potential use of VLPs produced as here described for the
development of a next generation vaccine for FMD control.
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